Trevena Inc (NASDAQ:TRVN) — Market Cap & Net Worth
Market Cap & Net Worth: Trevena Inc (TRVN)
Trevena Inc (NASDAQ:TRVN) has a market capitalization of $9.50K ($9.50K) as of May 4, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #31299 globally and #6006 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Trevena Inc's stock price $0.01 by its total outstanding shares 863788 (863.79K). Analyse cash flow conversion of Trevena Inc to see how efficiently the company converts income to cash.
Trevena Inc Market Cap History: 2015 to 2026
Trevena Inc's market capitalization history from 2015 to 2026. Data shows change from $5.67 Billion to $9.50K (-71.74% CAGR).
Trevena Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Trevena Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
4.99x
Trevena Inc's market cap is 4.99 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $5.67 Billion | $6.25 Million | -$50.53 Million | 906.98x | N/A |
| 2016 | $3.17 Billion | $3.75 Million | -$102.99 Million | 846.51x | N/A |
| 2018 | $232.14 Million | $5.73 Million | -$30.78 Million | 40.50x | N/A |
| 2019 | $453.97 Million | $31.00K | -$24.87 Million | 14644.34x | N/A |
| 2020 | $1.16 Billion | $3.07 Million | -$29.37 Million | 376.45x | N/A |
| 2021 | $314.47 Million | $567.00K | -$51.16 Million | 554.63x | N/A |
| 2022 | $30.88 Million | $-418.00K | -$53.67 Million | -73.88x | N/A |
| 2023 | $15.59 Million | $3.12 Million | -$40.29 Million | 4.99x | N/A |
Competitor Companies of TRVN by Market Capitalization
Companies near Trevena Inc in the global market cap rankings as of May 4, 2026.
Key companies related to Trevena Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $107.56 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #367 globally with a market cap of $72.88 Billion USD.
- UCB SA (BR:UCB): Ranked #517 globally with a market cap of $51.45 Billion USD ( €44.01 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #568 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #223 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $107.56 Billion | $423.92 |
| #367 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $72.88 Billion | $701.42 |
| #517 | UCB SA | BR:UCB | $51.45 Billion | €231.20 |
| #568 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
Trevena Inc Historical Marketcap From 2015 to 2026
Between 2015 and today, Trevena Inc's market cap moved from $5.67 Billion to $ 9.50K, with a yearly change of -71.74%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $9.50K | -8.33% |
| 2025 | $10.37K | -99.29% |
| 2024 | $1.46 Million | -90.64% |
| 2023 | $15.59 Million | -49.50% |
| 2022 | $30.88 Million | -90.18% |
| 2021 | $314.47 Million | -72.78% |
| 2020 | $1.16 Billion | +154.49% |
| 2019 | $453.97 Million | +95.56% |
| 2018 | $232.14 Million | -73.12% |
| 2017 | $863.79 Million | -72.79% |
| 2016 | $3.17 Billion | -44.00% |
| 2015 | $5.67 Billion | -- |
End of Day Market Cap According to Different Sources
On May 4th, 2026 the market cap of Trevena Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $9.50K USD |
| MoneyControl | $9.50K USD |
| MarketWatch | $9.50K USD |
| marketcap.company | $9.50K USD |
| Reuters | $9.50K USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Trevena Inc
Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV734, a small molecule G protein biased ligand of the… Read more